Brief: AC Immune SA - ACI-7104.056 Is Well Tolerated With No Safety Issues Reported To Date
02/04/2025 11:06
April 2 (Reuters) - AC Immune SA ACIU.O: AC IMMUNE SA - ACI-7104.056 IS WELL TOLERATED WITH NO SAFETY ISSUES REPORTED TO DATE AC IMMUNE REPORTS FURTHER POSITIVE INTERIM RESULTS FROM PHASE 2 TRIAL OF ACI-7104.056 ACTIVE IMMUNOTHERAPY IN EARLY PARKINSON’S DISEASE Source text: ID:nGNX6K9fwn Further company coverage: ACIU.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AC Immune SA
See all newsBrief: Ac Immune To Receive Research Grant From Goradia Family For Development Of Aci-7104 In Parkinson’S Disease
AC Immune Q1 net loss narrows on lower expenses
Brief: AC Immune Announces Amendment To Morphomer ® Tau License And Collaboration Agreement With Lilly
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture